Evidence map›Paper›PMID 32577633›Full record

ArticlebioRxiv : the preprint server for biology2020

Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2.

Kyle Rosenke, Michael A Jarvis, Friederike Feldmann, Benjamin Schwarz, Atsushi Okumura, Jamie Lovaglio, Greg Saturday, Patrick W Hanley, Kimberly Meade-White, Brandi N Williamson and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 3 countries.

Kyle RosenkeLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Michael A JarvisUniversity of Plymouth; and The Vaccine Group Ltd, Plymouth, Devon, UK.
Friederike FeldmannRocky Mountain Veterinary Branch, National Institutes of Health, Hamilton, MT, USA.
Benjamin SchwarzLaboratory of Bacteriology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Atsushi OkumuraLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Jamie LovaglioRocky Mountain Veterinary Branch, National Institutes of Health, Hamilton, MT, USA.
Greg SaturdayRocky Mountain Veterinary Branch, National Institutes of Health, Hamilton, MT, USA.
Patrick W HanleyRocky Mountain Veterinary Branch, National Institutes of Health, Hamilton, MT, USA.
Kimberly Meade-WhiteLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Brandi N WilliamsonLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Frederick HansenLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Lizette Perez-PerezLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Shanna LeventhalLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Tsing-Lee Tang-HuauLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Martha NasonBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institute of Health.
Julie CallisonLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Elaine HaddockLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Dana ScottRocky Mountain Veterinary Branch, National Institutes of Health, Hamilton, MT, USA.
Graham SewellThe Leicester School of Pharmacy, De Montfort University, Leicester, UK.
Catharine M BosioLaboratory of Bacteriology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
David HawmanLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Emmie de WitLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
Heinz FeldmannLaboratory of Virology, National Institutes of Health, Hamilton, MT, USA.
National Institutes of Health · USDe Montfort University · GBNational Institute of Infectious Diseases · JPUniversity of Plymouth · GB

Funding

H1N1 Influenza Disease Modeling and TransmissionZIAAI001088 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FELDMANN, HEINRICH · 2010 to 2023
$13.7M
SARS-CoV-2: Pathogenesis and Countermeasure DevelopmentZIAAI001300 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FELDMANN, HEINRICH · 2020 to 2023
$3.3M
Animal Research Support of COVID StudiesZICAI001330 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HANLEY, PATRICK · 2020 to 2022
$3.2M
Effect of SARS-CoV-2 on host metabolism and its influence on innate and adaptive immunityZIAAI001281 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BOSIO, CATHARINE · 2020 to 2025
$1.1M
6 · The paper itself

Abstract

We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in two animal models. When used for prophylaxis or treatment neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. In conclusion, our preclinical animal studies do not support the use of HCQ in prophylaxis/treatment of COVID-19.

Identifiers

PMID32577633
PMCPMC7301902
OpenAlexW3035724523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.